Nephron Pharmaceuticals, a West Columbia‑based manufacturer of sterile injectable drugs, issued a corporate statement on Monday confirming a major leadership transition. The company said chief executive officer and co‑owner Lou Kennedy has “departed” her role. Haywood Miller, a longtime executive with the firm, will serve as interim CEO while the board conducts a search for a permanent leader.
Company cites strong foundation and future opportunities
In the statement, Miller emphasized Nephron’s “strong foundation built on an exceptional team, trusted customer relationships, and world‑class manufacturing capabilities,” adding that the “opportunity ahead is significant.” The interim chief highlighted the company’s ongoing contracts with major health‑care providers and its commitment to maintaining high‑quality production standards.
Reports suggest the Kennedys were forced out
Multiple sources familiar with the situation told FITSNews that both Lou Kennedy and her husband, Bill Kennedy—who serves as chief business development officer and co‑owner—were “pushed out” of their positions. According to those sources, the Kennedys were escorted from the company’s West Columbia complex, a detail not mentioned in the official release.
The corporate announcement thanked Lou Kennedy “for her leadership and her many years of service to Nephron” but made no reference to Bill Kennedy’s departure. The omission has fueled speculation about the circumstances surrounding the leadership change.
Impact on the local economy
Nephron Pharmaceuticals is a significant employer in the Midlands region, providing jobs for dozens of skilled workers and supporting a supply chain of local vendors. The leadership shift could affect ongoing projects and future hiring plans, though Miller assured employees that operations would continue uninterrupted.
Local officials have not yet commented on the development, but the company’s continued presence is viewed as important for the economic health of West Columbia and the broader Upstate South Carolina area.
What comes next?
The board has indicated that a thorough search for a permanent CEO will begin immediately. Industry observers note that stability at the top is crucial for Nephron, especially as the pharmaceutical sector faces heightened regulatory scrutiny and supply‑chain challenges nationwide.
Stakeholders, including customers, suppliers, and local community leaders, will be watching the transition closely to gauge how the new leadership will navigate these pressures while preserving the company’s reputation for quality manufacturing.
Background on Nephron Pharmaceuticals
Founded in the early 2000s, Nephron has grown into a nationally recognized producer of sterile injectable medications used in hospitals and clinics across the United States. The firm prides itself on rigorous quality controls and has earned multiple certifications for its manufacturing processes.
As the story develops, HyperLocal Loop will continue to provide updates on the leadership transition and its implications for West Columbia’s business community.
Original reporting: FITSNews — read the source article.
